ALENTIS’ UNIQUE CLDN1 MONOCLONAL ANTIBODIES
CAN REVERT THE EXTRACELLULAR MATRIX TO ITS
HEALTHY STATE IN CANCERS AND ORGAN TISSUES
CLDN1 mAb has been designed with an effector function directly targeting cancer while silencing CLDN1-mediated carcinogenic signaling and opening up the stiff extracellular matrix (ECM) in tumors with immune evasive properties. IND clearance was received for a Phase 1/2 first-in-human clinical trial in head and neck squamous cell carcinoma (HNSCC). The trial is expected to start during the second half of 2023.
ALE.C04 received FDA Fast Track designation for the treatment of CLDN1 positive HNSCC.
CLDN1 mAb has been designed with a silenced effector function to target the stiff ECM of fibrotic tissues and organs and is currently under development for kidney, lung, and liver fibrosis. ALE.F02’s translational data predict robust efficacy and safety across multiple organ fibrosis indications. Topline data from a Phase 1 clinical trial in healthy volunteers were reported in 2023, several other clinical trials are planned to start during 2023.